{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:46:08Z","timestamp":1792806368551,"version":"4.5.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2011,11,4]],"date-time":"2011-11-04T00:00:00Z","timestamp":1320364800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Neurol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1186\/1471-2377-11-140","type":"journal-article","created":{"date-parts":[[2011,11,19]],"date-time":"2011-11-19T07:39:43Z","timestamp":1321688383000},"source":"Crossref","is-referenced-by-count":26,"title":["Rationale and design of a prospective study: Cervical Dystonia Patient Registry for Observation of OnaBotulinumtoxinA Efficacy (CD PROBE)"],"prefix":"10.1186","volume":"11","author":[{"given":"Joseph","family":"Jankovic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles H","family":"Adler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P David","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Comella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Stacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Schwartz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan M","family":"Sutch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F","family":"Brin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Papapetropoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2011,11,4]]},"reference":[{"key":"539_CR1","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.parkreldis.2007.02.005","volume":"13","author":"J Jankovic","year":"2007","unstructured":"Jankovic J, Tsui J, Bergeron C: Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord. 2007, 13: 411-416. 10.1016\/j.parkreldis.2007.02.005.","journal-title":"Parkinsonism Relat Disord"},{"issue":"Suppl 1","key":"539_CR2","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0733-8619(08)80003-5","volume":"26","author":"M Stacy","year":"2008","unstructured":"Stacy M: Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin. 2008, 26 (Suppl 1): 23-42.","journal-title":"Neurol Clin"},{"key":"539_CR3","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1017\/S0317167100031619","volume":"18","author":"P Rondot","year":"1991","unstructured":"Rondot P, Marchand MP, Dellatolas G: Spasmodic torticollis--review of 220 patients. Can J Neurol Sci. 1991, 18: 143-151.","journal-title":"Can J Neurol Sci"},{"key":"539_CR4","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1002\/mds.10127","volume":"17","author":"L Camfield","year":"2002","unstructured":"Camfield L, Ben-Shlomo Y, Warner TT: Impact of cervical dystonia on quality of life. Mov Disord. 2002, 17: 838-841. 10.1002\/mds.10127.","journal-title":"Mov Disord"},{"key":"539_CR5","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S1474-4422(06)70574-9","volume":"5","author":"J Jankovic","year":"2006","unstructured":"Jankovic J: Treatment of dystonia. Lancet Neurol. 2006, 5: 864-872. 10.1016\/S1474-4422(06)70574-9.","journal-title":"Lancet Neurol"},{"key":"539_CR6","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1136\/jnnp.2003.034702","volume":"75","author":"J Jankovic","year":"2004","unstructured":"Jankovic J: Botulinum toxin in clinical practice. J Neurol Neurosurg Psychiatry. 2004, 75: 951-957. 10.1136\/jnnp.2003.034702.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"539_CR7","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1056\/NEJMra055549","volume":"355","author":"D Tarsy","year":"2006","unstructured":"Tarsy D, Simon DK: Dystonia. N Engl J Med. 2006, 355: 818-829. 10.1056\/NEJMra055549.","journal-title":"N Engl J Med"},{"key":"539_CR8","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","volume":"70","author":"DM Simpson","year":"2008","unstructured":"Simpson DM, Blitzer A, Brashear A, Comella C, Dubinsky R, Hallett M, Jankovic J, Karp B, Ludlow CL, Miyasaki JM, Naumann M, So Y: Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008, 70: 1699-1706. 10.1212\/01.wnl.0000311389.26145.95.","journal-title":"Neurology"},{"key":"539_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/B978-0-12-374105-9.00098-8","volume-title":"Encyclopedia of Movement Disorders","author":"J Jankovic","year":"2010","unstructured":"Jankovic J: Botulinum toxin. Encyclopedia of Movement Disorders. Edited by: Kompoliti K, Verhagen Metman L. 2010, Oxford: Academic Press, 1: 144-150."},{"key":"539_CR10","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1001\/jama.2010.1937","volume":"305","author":"A Albanese","year":"2011","unstructured":"Albanese A: Terminology for preparations of botulinum neurotoxins: what a difference a name makes. JAMA. 2011, 305: 89-90. 10.1001\/jama.2010.1937.","journal-title":"JAMA"},{"issue":"Suppl 1","key":"539_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S0733-8619(08)80006-0","volume":"26","author":"G Sheean","year":"2008","unstructured":"Sheean G: Cervical dystonia: unresolved issues and future challenges. Neurol Clin. 2008, 26 (Suppl 1): 66-76.","journal-title":"Neurol Clin"},{"key":"539_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1212\/WNL.51.3.815","volume":"51","author":"JW Brans","year":"1998","unstructured":"Brans JW, Aramideh M, Koelman JH, Lindeboom R, Speelman JD, Ongerboer de Visser BW: Electromyography in cervical dystonia: changes after botulinum and trihexyphenidyl. Neurology. 1998, 51: 815-819.","journal-title":"Neurology"},{"key":"539_CR13","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1212\/WNL.42.4.878","volume":"42","author":"CL Comella","year":"1992","unstructured":"Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG: Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology. 1992, 42: 878-882.","journal-title":"Neurology"},{"key":"539_CR14","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.1002\/mus.1185","volume":"24","author":"RL Barbano","year":"2001","unstructured":"Barbano RL: Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is useful. Muscle Nerve. 2001, 24: 1567-1568. 10.1002\/mus.1185.","journal-title":"Muscle Nerve"},{"key":"539_CR15","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/mus.1186","volume":"24","author":"J Jankovic","year":"2001","unstructured":"Jankovic J: Needle EMG guidance for injection of botulinum toxin. Needle EMG guidance is rarely required. Muscle Nerve. 2001, 24: 1568-1570. 10.1002\/mus.1186.","journal-title":"Muscle Nerve"},{"key":"539_CR16","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1007\/s00415-002-0773-6","volume":"249","author":"J M\u00fcller","year":"2002","unstructured":"M\u00fcller J, Kemmler G, Wissel J, Schneider A, Voller B, Grossmann J, Diez J, Homann N, Wenning GK, Schnider P, Poewe W: The impact of blepharospasm and cervical dystonia on health-related quality of life and depression. J Neurol. 2002, 249: 842-846. 10.1007\/s00415-002-0733-1.","journal-title":"J Neurol"},{"key":"539_CR17","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1136\/jnnp.72.5.608","volume":"72","author":"Y Ben-Shlomo","year":"2002","unstructured":"Ben-Shlomo Y, Camfield L, Warner T: What are the determinants of quality of life in people with cervical dystonia?. J Neurol Neurosurg Psychiatry. 2002, 72: 608-614. 10.1136\/jnnp.72.5.608.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"539_CR18","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1111\/j.1468-1331.2007.01922.x","volume":"14","author":"IM Skogseid","year":"2007","unstructured":"Skogseid IM, Malt UF, R\u00f8islien J, Kerty E: Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia. Eur J Neurol. 2007, 14: 1129-1137. 10.1111\/j.1468-1331.2007.01922.x.","journal-title":"Eur J Neurol"},{"key":"539_CR19","first-page":"95","volume":"22","author":"J Slawek","year":"2007","unstructured":"Slawek J, Friedman A, Potulska A, Krystkowiak P, Gervais C, Banach M, Ochudlo S, Budrewicz S, Reclawowicz D, Rynkowski M, Opala G: Factors affecting the health-related quality of life of patients with cervical dystonia and the impact of botulinum toxin type A injections. Funct Neurol. 2007, 22: 95-100.","journal-title":"Funct Neurol"},{"key":"539_CR20","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1212\/01.wnl.0000249310.25427.f2","volume":"67","author":"SJ Cano","year":"2006","unstructured":"Cano SJ, Hobart JC, Edwards M, Fitzpatrick R, Bhatia K, Thompson AJ, Warner TT: CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology. 2006, 67: 2230-2232. 10.1212\/01.wnl.0000249310.25427.f2.","journal-title":"Neurology"},{"key":"539_CR21","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1136\/jnnp.71.2.193","volume":"71","author":"R Hilker","year":"2001","unstructured":"Hilker R, Schischniaschvili M, Ghaemi M, Jacobs A, Rudolf J: Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia. J Neurol Neurosurg Psychiatry. 2001, 71: 193-199. 10.1136\/jnnp.71.2.193.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"539_CR22","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1212\/WNL.50.5.1461","volume":"50","author":"JW Brans","year":"1998","unstructured":"Brans JW, Lindeboom R, Aramideh M, Speelman JD: Long-term effect of botulinum toxin on impairment and functional health in cervical dystonia. Neurology. 1998, 50: 1461-1463.","journal-title":"Neurology"},{"key":"539_CR23","first-page":"211","volume-title":"Therapy with Botulinum Toxin","author":"E Consky","year":"1994","unstructured":"Consky E, Lang A: Clinical assessments of patients with cervical dystonia. Therapy with Botulinum Toxin. Edited by: Jankovic J, Hallett M. 1994, New York: Marcel Dekker, Inc, 211-237."},{"key":"539_CR24","doi-asserted-by":"publisher","first-page":"A587","DOI":"10.1212\/WNL.0b013e31820cdb17","volume":"76","author":"S Papapetropoulos","year":"2011","unstructured":"Papapetropoulos S, Rosa K, Comella C, Boo LM, Brin MF: Validity and reliability of the Pictorial Spasmodic Torticollis Rating Scale (P-STRS). Neurology. 2011, 76: A587-10.1212\/WNL.0b013e31820cdb17.","journal-title":"Neurology"},{"key":"539_CR25","volume-title":"Manual for the ECDEU Assessment Battery","year":"1976","unstructured":"Guy W, Bonato RR, editors: Manual for the ECDEU Assessment Battery. 1976, Chevy Chase: National Institute of Mental Health"},{"key":"539_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.pain.2004.09.012","volume":"113","author":"RH Dworkin","year":"2005","unstructured":"Dworkin RH, Turk DC, Farrar JT, Haythornthwaite JA, Jensen MP, Katz NP, et al: Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005, 113: 9-19. 10.1016\/j.pain.2004.09.012.","journal-title":"Pain"},{"key":"539_CR27","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.pain.2003.08.001","volume":"106","author":"DC Turk","year":"2003","unstructured":"Turk DC, Dworkin RH, Allen RR, Bellamy N, Brandenburg N, Carr DB, Cleeland C, Dionne R, Farrar JT, Galer BS, Hewitt DJ, Jadad AR, Katz NP, Kramer LD, Manning DC, McCormick CG, McDermott MP, McGrath P, Quessy S, Rappaport BA, Robinson JP, Royal MA, Simon L, Stauffer JW, Stein W, Tollett J, Witter J: Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain. 2003, 106: 337-345. 10.1016\/j.pain.2003.08.001.","journal-title":"Pain"},{"key":"539_CR28","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1212\/01.WNL.0000142962.11881.26","volume":"63","author":"SJ Cano","year":"2004","unstructured":"Cano SJ, Warner TT, Linacre JM, Bhatia KP, Thompson AJ, Fitzpatrick R, Hobart JC: Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58). Neurology. 2004, 63: 1629-1633.","journal-title":"Neurology"},{"key":"539_CR29","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1002\/mds.22622","volume":"24","author":"ES Molho","year":"2009","unstructured":"Molho ES, Agarwal N, Regan K, Higgins DS, Factor SA: Effect of cervical dystonia on employment: a retrospective analysis of the ability of treatment to restore premorbid employment status. Mov Disord. 2009, 24: 1384-1387. 10.1002\/mds.22622.","journal-title":"Mov Disord"},{"key":"539_CR30","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1136\/jnnp.66.5.612","volume":"66","author":"PA Hanna","year":"1999","unstructured":"Hanna PA, Jankovic J, Vincent A: Comparison of mouse bioassay and immunoprecipitation assay for botulinum toxin antibodies. J Neurol Neurosurg Psychiatry. 1999, 66: 612-616. 10.1136\/jnnp.66.5.612.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"539_CR31","volume-title":"Toxicon","author":"J Baizabal Carvallo","year":"2011","unstructured":"Baizabal Carvallo J, Jankovic J, Pappert E: Flu-like symptoms following botulinum toxin therapy. Toxicon 2011."},{"key":"539_CR32","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1212\/WNL.41.7.1088","volume":"41","author":"J Jankovic","year":"1991","unstructured":"Jankovic J, Leder S, Warner D, Schwartz K: Cervical dystonia: clinical findings and associated movement disorders. Neurology. 1991, 41: 1088-1091.","journal-title":"Neurology"},{"key":"539_CR33","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1002\/mds.870060206","volume":"6","author":"J Chan","year":"1991","unstructured":"Chan J, Brin MF, Fahn S: Idiopathic cervical dystonia: clinical characteristics. Mov Disord. 1991, 6: 119-126. 10.1002\/mds.870060206.","journal-title":"Mov Disord"},{"key":"539_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/BF02850184","volume":"22","author":"A Brashear","year":"2005","unstructured":"Brashear A, Hogan P, Wooten-Watts M, Marchetti A, Magar R, Martin J: Longitudinal assessment of the dose consistency of botulinum toxin type A (BOTOX) for cervical dystonia. Adv Ther. 2005, 22: 49-55. 10.1007\/BF02850184.","journal-title":"Adv Ther"},{"key":"539_CR35","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.parkreldis.2010.03.002","volume":"16","author":"D Truong","year":"2010","unstructured":"Truong D, Brodsky M, Lew M, Brashear A, Jankovic J, Molho E, Orlova O, Timerbaeva S: Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010, 16: 316-323. 10.1016\/j.parkreldis.2010.03.002.","journal-title":"Parkinsonism Relat Disord"},{"key":"539_CR36","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1002\/mds.21724","volume":"23","author":"EJ Pappert","year":"2008","unstructured":"Pappert EJ, Germanson T: Botulinum toxin type B vs. type A in toxin-naive patients with cervical dystonia: randomized, double-blind, noninferiority trial. Mov Disord. 2008, 23: 510-517. 10.1002\/mds.21724.","journal-title":"Mov Disord"},{"key":"539_CR37","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1212\/01.wnl.0000183055.81056.5c","volume":"65","author":"CL Comella","year":"2005","unstructured":"Comella CL, Jankovic J, Shannon KM, Tsui J, Swenson M, Leurgans S, Fan W: Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005, 65: 1423-1429. 10.1212\/01.wnl.0000183055.81056.5c.","journal-title":"Neurology"},{"key":"539_CR38","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1002\/mds.20531","volume":"20","author":"SA Factor","year":"2005","unstructured":"Factor SA, Molho ES, Evans S, Feustel PJ: Efficacy and safety of repeated doses of botulinum toxin type B in type A resistant and responsive cervical dystonia. Mov Disord. 2005, 20: 1152-1160. 10.1002\/mds.20531.","journal-title":"Mov Disord"}],"container-title":["BMC Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-11-140.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2377-11-140\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2377-11-140","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T10:00:50Z","timestamp":1497952850000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmcneurol.biomedcentral.com\/articles\/10.1186\/1471-2377-11-140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,4]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["539"],"URL":"https:\/\/doi.org\/10.1186\/1471-2377-11-140","relation":{},"ISSN":["1471-2377"],"issn-type":[{"value":"1471-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,4]]},"article-number":"140"}}